(Q37741285)

1 July 2019

review article

1 reference

title

Pharmacological therapy in Parkinson's disease: focus on neuroprotection (English)

1 reference

1 July 2019

1 reference

1 reference

Zsigmond Tamás Kincses

1

1 reference

1 July 2019

Laszlo Vecsei

2

1 reference

1 July 2019

Laszlo Vecsei

2

object named as

Laszlo Vecsei

1 reference

PubMed publication ID

20438581

22 August 2017

author name string

Zsigmond Tamas Kincses

1

1 reference

PubMed publication ID

20438581

22 August 2017

publication date

23 April 2010

1 reference

1 July 2019

CNS Neuroscience & Therapeutics

published in

1 reference

1 July 2019

volume

17

1 reference

1 July 2019

issue

5

1 reference

1 July 2019

page(s)

345-367

1 reference

1 July 2019

Parkinson's disease and parkinsonism in a longitudinal study: two-fold higher incidence in men. ILSA Working Group. Italian Longitudinal Study on Aging.

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Cognitive change in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Electrophysiological correlates of visual categorization: evidence for cognitive dysfunctions in early Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Corticostriatal circuitry mediates fast-track visual categorization.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Concentric hyalin intraneuronal inclusions of Lewy type in the brains of elderly persons (50 incidental cases): relationship to parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Formation and development of Lewy pathology: a critical update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Staging of brain pathology related to sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Bioenergetic approaches for neuroprotection in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Genetic findings in Parkinson's disease and translation into treatment: a leading role for mitochondria?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Alterations in the distribution of glutathione in the substantia nigra in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Alterations in m-RNA expression for Cu,Zn-superoxide dismutase and glutathione peroxidase in the basal ganglia of MPTP-treated marmosets and patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Iron-melanin complex in substantia nigra of parkinsonian brains: an x-ray microanalysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Hyperechogenicity of the substantia nigra in healthy controls is related to MRI changes and to neuronal loss as determined by F-Dopa PET.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

T2 relaxation time in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Cytotoxic and genotoxic potential of dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Origin and functional consequences of the complex I defect in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The cybrid model of sporadic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A novel mitochondrial signaling pathway activated by visible-to-near infrared radiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

K-ATP channels promote the differential degeneration of dopaminergic midbrain neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effects of mitochondrial toxins on the brain amino acid concentrations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Distribution of major histocompatibility complex class II-positive microglia and cytokine profile of Parkinson's disease brains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Tumor necrosis factor-alpha (TNF-alpha) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Evaluation of interleukins, ACTH, cortisol and prolactin concentrations in the blood of patients with parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Association of circulating TNF-alpha and IL-6 with ageing and parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Interleukin-1 beta and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Microglial activation and dopamine terminal loss in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A CD14 monocyte receptor polymorphism and genetic susceptibility to Parkinson's disease for females.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Neuroprotective effects of creatine in a transgenic animal model of amyotrophic lateral sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Ablation of the inflammatory enzyme myeloperoxidase mitigates features of Parkinson's disease in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Caspase-11 mediates inflammatory dopaminergic cell death in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Microglia and inflammation-mediated neurodegeneration: multiple triggers with a common mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Relationship between alpha synuclein phosphorylation, proteasomal inhibition and cell death: relevance to Parkinson's disease pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

alpha-Synuclein: a therapeutic target for Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Is Parkinson's disease a prion disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Transplanted dopaminergic neurons develop PD pathologic changes: a second case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

ER stress signaling and the BCL-2 family of proteins: from adaptation to irreversible cellular damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

ER stress and neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Calcium homeostasis, selective vulnerability and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Apoptosis: A Basic Biological Phenomenon with Wideranging Implications in Tissue Kinetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Neuroinflammation in Parkinson's disease: a target for neuroprotection?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Genetic ablation of tumor necrosis factor-alpha (TNF-alpha) and pharmacological inhibition of TNF-synthesis attenuates MPTP toxicity in mouse striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Tumor necrosis factor-alpha receptor ablation in a chronic MPTP mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Role of TNF-alpha receptors in mice intoxicated with the parkinsonian toxin MPTP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Deficiency of TNF receptors suppresses microglial activation and alters the susceptibility of brain regions to MPTP-induced neurotoxicity: role of TNF-alpha1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Fas and Fas-L expression in Huntington's disease and Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Regulation of dopaminergic loss by Fas in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Defective Fas expression exacerbates neurotoxicity in a model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Low concentrations of 1-methyl-4-phenylpyridinium ion induce caspase-mediated apoptosis in human SH-SY5Y neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

JNK-mediated induction of cyclooxygenase 2 is required for neurodegeneration in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Gene transfer of the JNK interacting protein-1 protects dopaminergic neurons in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mitochondrial membrane permeabilisation by Bax/Bak

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Apoptosis and human diseases: mitochondrion damage and lethal role of released cytochrome C as proapoptotic protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mitochondria as the target of the pro-apoptotic protein Bax.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Geographical difference in Parkinson's disease prevalence within West Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Familial and environmental risk factors in Parkinson's disease: a case-control study in north-east Italy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The risk of Parkinson's disease with exposure to pesticides, farming, well water, and rural living

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Multiple risk factors for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Update in the epidemiology of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Epidemiologic studies of environmental exposures in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mutation in the alpha-synuclein gene identified in families with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The role of alpha-synuclein in neurodegenerative diseases: a potential target for new treatment strategies?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Alpha-synuclein locus duplication as a cause of familial Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

alpha-Synuclein locus triplication causes Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Autosomal recessive early onset parkinsonism is linked to three loci: PARK2, PARK6, and PARK7

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Parkin prevents mitochondrial swelling and cytochrome c release in mitochondria-dependent cell death.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Influence of heterozygosity for parkin mutation on onset age in familial Parkinson disease: the GenePD study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The ubiquitin pathway in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Association studies of multiple candidate genes for Parkinson's disease using single nucleotide polymorphisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Substrate binding and catalysis by ubiquitin C-terminal hydrolases: identification of two active site residues

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Hereditary early-onset Parkinson's disease caused by mutations in PINK1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mitochondrial import and enzymatic activity of PINK1 mutants associated to recessive parkinsonism.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Localization of a novel locus for autosomal recessive early-onset parkinsonism, PARK6, on human chromosome 1p35-p36

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

DJ-1 is a redox-dependent molecular chaperone that inhibits alpha-synuclein aggregate formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mutations in the DJ-1 gene associated with autosomal recessive early-onset parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

LRRK2 in Parkinson's disease: protein domains and functional insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Inhibition of fibril formation and toxicity of a fragment of alpha-synuclein by an N-methylated peptide analogue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Inhibiting aggregation of alpha-synuclein with human single chain antibody fragments

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Statins reduce neuronal alpha-synuclein aggregation in in vitro models of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effects of the cholesterol-lowering compound methyl-beta-cyclodextrin in models of alpha-synucleinopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

An unfolded putative transmembrane polypeptide, which can lead to endoplasmic reticulum stress, is a substrate of Parkin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Parkin functions as an E2-dependent ubiquitin- protein ligase and promotes the degradation of the synaptic vesicle-associated protein, CDCrel-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Parkin ubiquitinates the alpha-synuclein-interacting protein, synphilin-1: implications for Lewy-body formation in Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Ubiquitination of a new form of alpha-synuclein by parkin from human brain: implications for Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Lentiviral vector delivery of parkin prevents dopaminergic degeneration in an alpha-synuclein rat model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Loss of PINK1 causes mitochondrial functional defects and increased sensitivity to oxidative stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

PINK1 protects against oxidative stress by phosphorylating mitochondrial chaperone TRAP1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Wild-type PINK1 prevents basal and induced neuronal apoptosis, a protective effect abrogated by Parkinson disease-related mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Formation of a Stabilized Cysteine Sulfinic Acid Is Critical for the Mitochondrial Function of the Parkinsonism Protein DJ-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Aggresome-forming TTRAP mediates pro-apoptotic properties of Parkinson's disease-associated DJ-1 missense mutations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

DJ-1 and Parkin Modulate Dopamine-dependent Behavior and Inhibit MPTP-induced Nigral Dopamine Neuron Loss in Mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

PARK7 DJ-1 protects against degeneration of nigral dopaminergic neurons in Parkinson's disease rat model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

DJ-1-binding compounds prevent oxidative stress-induced cell death and movement defect in Parkinson's disease model rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Kinase activity is required for the toxic effects of mutant LRRK2/dardarin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Kinase activity of mutant LRRK2 mediates neuronal toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The Parkinson disease causing LRRK2 mutation I2020T is associated with increased kinase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Apoptotic mechanisms in mutant LRRK2-mediated cell death

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Identification of potential protein interactors of Lrrk2

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The chaperone activity of heat shock protein 90 is critical for maintaining the stability of leucine-rich repeat kinase 2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Parkinson disease in twins: an etiologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Conversion from sustained release carbidopa/levodopa to carbidopa/levodopa/entacapone (stalevo) in Parkinson disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Dopaminergic neurons intrinsic to the striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Immunohistochemical detection of L-DOPA-derived dopamine within serotonergic fibers in the striatum and the substantia nigra pars reticulata in Parkinsonian model rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Gain-of-function haplotypes in the vesicular monoamine transporter promoter are protective for Parkinson disease in women

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Role of oxidative changes in the degeneration of dopamine terminals after injection of neurotoxic levels of dopamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Does levodopa slow or hasten the rate of progression of Parkinson's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The dopamine agonist cabergoline provides neuroprotection by activation of the glutathione system and scavenging free radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Dopamine D2-type agonists protect mesencephalic neurons from glutamate neurotoxicity: mechanisms of neuroprotective treatment against oxidative stress.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Dopamine D2 receptor-mediated antioxidant and neuroprotective effects of ropinirole, a dopamine agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Role of cytochrome c as a stimulator of alpha-synuclein aggregation in Lewy body disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Protective effect of talipexole on MPTP-treated planarian, a unique parkinsonian worm model

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Pramipexole protects against MPTP toxicity in non-human primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Novel neuroprotective mechanisms of pramipexole, an anti-Parkinson drug, against endogenous dopamine-mediated excitotoxicity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Dopamine D3 receptor-preferring agonists induce neurotrophic effects on mesencephalic dopamine neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Brain-derived neurotrophic factor protects dopamine neurons against 6-hydroxydopamine and N-methyl-4-phenylpyridinium ion toxicity: involvement of the glutathione system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

BDNF is induced by wild-type alpha-synuclein but not by the two mutants, A30P or A53T, in glioma cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Inhibiting BDNF expression by antisense oligonucleotide infusion causes loss of nigral dopaminergic neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Brain-derived neurotrophic factor (BDNF) Val66Met polymorphisms in Parkinson's disease and age of onset

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Lack of association between the BDNF Val66Met polymorphism and Parkinson's disease in a Swedish population

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Interactions of monoamine oxidase with substrates and inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Pharmacological properties of the anti-Parkinson drug rasagiline; modification of endogenous brain amines, reserpine reversal, serotonergic and dopaminergic behaviours

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

D-deprenyl protects nigrostriatal neurons against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Novel bifunctional drugs targeting monoamine oxidase inhibition and iron chelation as an approach to neuroprotection in Parkinson's disease and other neurodegenerative diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The effect of deprenyl and levodopa on the progression of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A double-blind, delayed-start trial of rasagiline in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

NSAID use and the risk of Parkinson's disease: systematic review and meta-analysis of observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Nonsteroidal anti-inflammatory drugs may protect against Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

NSAID use and the risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Neuroprotective effects of non-steroidal anti-inflammatory drugs by direct scavenging of nitric oxide radicals

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Minocycline prevents nigrostriatal dopaminergic neurodegeneration in the MPTP model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A pilot clinical trial of creatine and minocycline in early Parkinson disease: 18-month results

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Glatiramer acetate-specific T cells in the brain express T helper 2/3 cytokines and brain-derived neurotrophic factorin situ

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Copolymer 1 induces T cells of the T helper type 2 that crossreact with myelin basic protein and suppress experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Secretion of brain-derived neurotrophic factor by glatiramer acetate-reactive T-helper cell lines: Implications for multiple sclerosis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Glatiramer acetate-specific T-helper 1- and 2-type cell lines produce BDNF: implications for multiple sclerosis therapy. Brain-derived neurotrophic factor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

CD4+ T cells from Copolymer-1 immunized mice protect dopaminergic neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Therapeutic immunization protects dopaminergic neurons in a mouse model of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Quantitative 1H magnetic resonance spectroscopic imaging determines therapeutic immunization efficacy in an animal model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Creatine and cyclocreatine attenuate MPTP neurotoxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The role of creatine kinase in inhibition of mitochondrial permeability transition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Inhibition of the mitochondrial permeability transition by creatine kinase substrates. Requirement for microcompartmentation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Neuroprotective mechanisms of creatine occur in the absence of mitochondrial creatine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Direct antioxidant properties of creatine

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Induction by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of lipid peroxidation in vivo in vitamin E deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Desferrioxamine and vitamin E protect against iron and MPTP-induced neurodegeneration in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Partial protection from the dopaminergic neurotoxin N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by four different antioxidants in the mouse.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effects of MPTP and vitamin E treatments on immune function in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Genetic vitamin E deficiency does not affect MPTP susceptibility in the mouse brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A pilot trial of high-dose alpha-tocopherol and ascorbate in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Biochemical, physiological and medical aspects of ubiquinone function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Dihydrolipoic acid maintains ubiquinone in the antioxidant active form by two-electron reduction of ubiquinone and one-electron reduction of ubisemiquinone

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effect of lipoic acid on redox state of coenzyme Q in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and diethyldithiocarbamate

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effect of coenzyme Q(10) on biochemical and morphological changes in experimental ischemia in the rat brain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Coenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Paraquat induces oxidative stress, neuronal loss in substantia nigra region and parkinsonism in adult rats: neuroprotection and amelioration of symptoms by water-soluble formulation of coenzyme Q10

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Unique technology for solubilization and delivery of highly lipophilic bioactive molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The role of kynurenines in disorders of the central nervous system: possibilities for neuroprotection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Mitochondria, metabolic disturbances, oxidative stress and the kynurenine system, with focus on neurodegenerative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Kynurenines in chronic neurodegenerative disorders: future therapeutic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Kynurenic acid antagonises responses to NMDA via an action at the strychnine-insensitive glycine receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Kynurenate and FG9041 have both competitive and non-competitive antagonist actions at excitatory amino acid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The Janus-face kynurenic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Quinolinic acid stimulates synaptosomal glutamate release and inhibits glutamate uptake into astrocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Quinolinic acid is a potent lipid peroxidant in rat brain homogenates

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Decreased expression of kynurenine aminotransferase-I (KAT-I) in the substantia nigra of mice after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Effect of 6-hydroxydopamine treatment on kynurenine aminotransferase-I (KAT-I) immunoreactivity of neurons and glial cells in the rat substantia nigra.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Protection of substantia nigra from MPP+ neurotoxicity by N-methyl-D-aspartate antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The non-NMDA glutamate receptor antagonists 6-cyano-7-nitroquinoxaline-2,3-dione and 2,3-dihydroxy-6-nitro-7-sulfamoylbenzo(f)quinoxaline, but not NMDA antagonists, block the intrastriatal neurotoxic effect of MPP+.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Increased neopterin production and tryptophan degradation in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Protection against quinolinic acid-mediated excitotoxicity in nigrostriatal dopaminergic neurons by endogenous kynurenic acid.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Kynurenine 3-mono-oxygenase inhibitors reduce glutamate concentration in the extracellular spaces of the basal ganglia but not in those of the cortex or hippocampus

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Prolonged kynurenine 3-hydroxylase inhibition reduces development of levodopa-induced dyskinesias in parkinsonian monkeys

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Protection Against N-methyl-D-aspartate Receptor-Mediated Neuronal Degeneration In Rat Brain by 7-chlorokynurenate and 3-amino-1-hydroxypyrrolid-2-one, Antagonists at The Allosteric Site for Glycine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

7-Chlorokynurenate Blocks NMDA Receptor-Mediated Neurotoxicity in Murine Cortical Culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

An Essay on the Shaking Palsy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

S18Y in ubiquitin carboxy-terminal hydrolase L1 (UCH-L1) associated with decreased risk of Parkinson's disease in Sweden

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

PARK6-linked parkinsonism occurs in several European families.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Genetics of Parkinson's disease and biochemical studies of implicated gene products: Commentary

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Incidence of parkinsonism and Parkinson disease in a general population: The Rotterdam Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Heterozygosity for a mutation in the parkin gene leads to later onset Parkinson disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Reduced BDNF mRNA Expression in the Parkinson's Disease Substantia Nigra

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

BDNF genetic variants are associated with onset age of familial Parkinson disease: GenePD Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

Protective Effect of the Energy Precursor Creatine Against Toxicity of Glutamate and β-Amyloid in Rat Hippocampal Neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1755-5949.2010.00150.X

The glutamate receptor ion channels

21 January 2018

1 reference

12 December 2020

The absence of reactive astrocytosis is indicative of a unique inflammatory process in Parkinson's disease

1 reference

12 December 2020

Systemic administration of 4-chlorokynurenine prevents quinolinate neurotoxicity in the rat hippocampus

1 reference

12 December 2020

Influence of interleukin-1beta gene polymorphisms on age-at-onset of sporadic Parkinson's disease

1 reference

12 December 2020

Visuo-cognitive dysfunctions in Parkinson's disease.

1 reference

12 December 2020

Neuroprotective effects of creatine in a transgenic mouse model of Huntington's disease.

1 reference

12 December 2020

Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamine

1 reference

12 December 2020

Reduction of lipid peroxidation in different rat brain areas after cabergoline treatment

1 reference

12 December 2020

1 reference

12 December 2020

1 reference

12 December 2020

Molecular aspects of alpha-tocotrienol antioxidant action and cell signalling

1 reference

12 December 2020

Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022.

1 reference

12 December 2020

The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications

1 reference

12 December 2020

Tumor necrosis factor gene polymorphisms in patients with sporadic Parkinson's disease

1 reference

12 December 2020

Molecular mechanisms of death-receptor-mediated apoptosis

1 reference

12 December 2020

An essay on the shaking palsy. 1817.

1 reference

12 December 2020

Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease

1 reference

12 December 2020

Dopaminergic contributions to the visual categorization of natural scenes: evidence from Parkinson's disease.

1 reference

12 December 2020

Dysfunction of mitochondrial complex I and the proteasome: interactions between two biochemical deficits in a cellular model of Parkinson's disease.

1 reference

12 December 2020

The importance of propargylamine moiety in the anti-Parkinson drug rasagiline and its derivatives in MAPK-dependent amyloid precursor protein processing

1 reference

12 December 2020

Toward identification of susceptibility genes for sporadic Parkinson's disease

1 reference

12 December 2020

A strategy for designing inhibitors of alpha-synuclein aggregation and toxicity as a novel treatment for Parkinson's disease and related disorders

1 reference

12 December 2020

Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members

1 reference

12 December 2020

Protective effect of TAT-delivered alpha-synuclein: relevance of the C-terminal domain and involvement of HSP70.

1 reference

12 December 2020

The natural history of Parkinson's disease in the pre-levodopa and post-levodopa eras

1 reference

12 December 2020

Alpha-synuclein aggregation in neurodegenerative diseases and its inhibition as a potential therapeutic strategy

1 reference

12 December 2020

Patient satisfaction with switching to Stalevo: an open-label evaluation in PD patients experiencing wearing-off (Simcom Study)

1 reference

12 December 2020

Case-control study of UCHL1 S18Y variant in Parkinson's disease

1 reference

12 December 2020

Kynurenines, Parkinson's disease and other neurodegenerative disorders: preclinical and clinical studies.

1 reference

12 December 2020

Role of microglia in inflammation-mediated degeneration of dopaminergic neurons: neuroprotective effect of interleukin 10

1 reference

12 December 2020

M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson's disease.

1 reference

12 December 2020

Tumor necrosis factor-alpha promoter polymorphism is associated with the risk of Parkinson's disease

1 reference

12 December 2020

DJ-1 and Parkin modulate dopamine-dependent behavior and inhibit MPTP-induced nigral dopamine neuron loss in mice

1 reference

12 December 2020

Induction of apoptosis and activation of JNK and p38 MAPK pathways in deoxynivalenol-treated cell lines.

1 reference

12 December 2020

Vitamin E supplements fail to protect mice from acute MPTP neurotoxicity.

1 reference

12 December 2020

Localization of L-DOPA uptake and decarboxylating neuronal structures in the cat brain using dopamine immunohistochemistry

1 reference

12 December 2020

Rare heterozygous parkin variants in French early-onset Parkinson disease patients and controls

1 reference

12 December 2020

Circulating interleukin-15 and RANTES chemokine in Parkinson’s disease

1 reference

12 December 2020

Interleukin-10 (IL10) and tumor necrosis factor α (TNF) gene polymorphisms in Parkinson's disease patients

1 reference

12 December 2020

The use of Stalevo in Hungary for patients with Parkinson disease and its effect on the quality of life

1 reference

12 December 2020

Controversies over the staging of alpha-synuclein pathology in Parkinson's disease

1 reference

12 December 2020

Lack of evidence for association of a UCH-L1 S18Y polymorphism with Parkinson's disease in a Han-Chinese population.

1 reference

12 December 2020

Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease.

1 reference

12 December 2020

Neuroprotection in Parkinson's disease and other neurodegenerative disorders: preclinical and clinical findings

1 reference

12 December 2020

Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model

1 reference

12 December 2020

[Long term experience with Stalevo in Szeged, Hungary].

1 reference

12 December 2020

Role of calcium ions in regulation of mammalian intramitochondrial metabolism

1 reference

12 December 2020

Abnormalities of the electron transport chain in idiopathic Parkinson's disease

1 reference

12 December 2020

Beta 2-microglobulin decrease in cerebrospinal fluid from parkinsonian patients

1 reference

12 December 2020

Cytotoxicity of 3-hydroxykynurenine in a neuronal hybrid cell line

1 reference

12 December 2020

Transition Metals, Ferritin, Glutathione, and Ascorbic Acid in Parkinsonian Brains

1 reference

12 December 2020

Phenylisopropylmethylpropinylamine (E-250), a new spectrum psychic energizer.

1 reference

12 December 2020

1 reference

12 December 2020

Comparative pharmacological analysis of the optical isomers of phenyl-isopropyl-methyl-propinylamine (E-250)

1 reference

12 December 2020

Coupling of dopamine oxidation (monoamine oxidase activity) to glutathione oxidation via the generation of hydrogen peroxide in rat brain homogenates

1 reference

12 December 2020

Transforming growth factor-beta 1 levels are elevated in the striatum and in ventricular cerebrospinal fluid in Parkinson's disease

1 reference

12 December 2020

Anatomy and physiology of glutamate in the CNS.

1 reference

12 December 2020

Brain beta 2-microglobulin levels are elevated in the striatum in Parkinson's disease

1 reference

12 December 2020

Interleukin-1 beta, interleukin-6, epidermal growth factor and transforming growth factor-alpha are elevated in the brain from parkinsonian patients

1 reference

12 December 2020

Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro

1 reference

12 December 2020

Nigral dopaminergic cell loss in vitamin E deficient rats

1 reference

12 December 2020

Bromocriptine scavenges methamphetamine-induced hydroxyl radicals and attenuates dopamine depletion in mouse striatum

1 reference

12 December 2020

Mitochondrial respiratory failure in skeletal muscle from patients with Parkinson's disease and multiple system atrophy

1 reference

12 December 2020

Coenzyme Q10 and nicotinamide block striatal lesions produced by the mitochondrial toxin malonate

1 reference

12 December 2020

Mitochondrial respiratory chain activity in skeletal muscle from patients with Parkinson's disease

1 reference

12 December 2020

Apamin-sensitive Ca(2+)-activated K+ channels regulate pacemaker activity in nigral dopamine neurons.

1 reference

12 December 2020

Interleukin (IL)-1 beta, IL-2, IL-4, IL-6 and transforming growth factor-alpha levels are elevated in ventricular cerebrospinal fluid in juvenile parkinsonism and Parkinson's disease.

1 reference

12 December 2020

The role of transition metals in the pathogenesis of Parkinson's disease

1 reference

12 December 2020

Scavenging effects of dopamine agonists on nitric oxide radicals.

1 reference

12 December 2020

Interleukin-2 but not basic fibroblast growth factor is elevated in parkinsonian brain. Short communication

1 reference

12 December 2020

Enzyme-catalyzed production of the neuroprotective NMDA receptor antagonist 7-chlorokynurenic acid in the rat brain in vivo

1 reference

12 December 2020

Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.

1 reference

12 December 2020

Electron transport-linked ubiquinone-dependent recycling of alpha-tocopherol inhibits autooxidation of mitochondrial membranes

1 reference

12 December 2020

Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.

1 reference

12 December 2020

L-Type calcium channels mediate a slow excitatory synaptic transmission in rat midbrain dopaminergic neurons.

1 reference

12 December 2020

Antibodies from patients with Parkinson's disease react with protein modified by dopamine oxidation.

1 reference

12 December 2020

Subthalamic nucleus-mediated excitotoxicity in Parkinson's disease: a target for neuroprotection.

1 reference

12 December 2020

Protective effects of the antiparkinsonian drugs talipexole and pramipexole against 1-methyl-4-phenylpyridinium-induced apoptotic death in human neuroblastoma SH-SY5Y cells.

1 reference

12 December 2020

CEP-1347/KT-7515, an inhibitor of c-jun N-terminal kinase activation, attenuates the 1-methyl-4-phenyl tetrahydropyridine-mediated loss of nigrostriatal dopaminergic neurons In vivo.

1 reference

12 December 2020

10.1111/J.1755-5949.2010.00150.X

Identifiers

DOI

1 reference

1 July 2019

PMC publication ID

6493808

1 reference

1 July 2019

PubMed publication ID

20438581

1 reference

1 July 2019